Description
MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a K d of 4.1 µM. MB710 shows anticancer activity in p53-Y220C cell linesIn VitroMB710 (0-200 µM; 72 hours) shows relatively low toxicity against all cell lines tested at concentrations up to 60 µM, while showing initial selective viability reduction at higher concentrations. MB710 (72 hours) treats cancer cell lines NUGC3, NUGC4, WI38 and SW1088, with IC 50 s of 90, 120, >120, >120 µM, respectively. MB710 (0-120 µM; 72 hours; HUH-7 cells) shows stronger cytotoxic effects in presence of p53-Y220C. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: NUGC3 (mutant p53 Y220C), HUH-7 (mutant p53 Y220C), NUGC4 (p53 WT), HUH-6 cells (p53 WT) Concentration: 0-200 µM Incubation Time: 72 hours Result: Showed relatively low toxicity against all cell lines tested at concentrations up to 60 µM. NUGC3 was the most sensitive cell line.Form:SolidIC50& Target:Kd: 4 µM (p53-Y220C)